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Single variant or single gene analyses generally account for only a small proportion of the phenotypic variation in
complex traits. Alternatively, gene set or pathway association analyses are playing an increasingly important role in
uncovering genetic architectures of complex traits through the identification of systematic genetic interactions. Two
dominant paradigms for gene set analyses are association analyses based on SNP genotypes and those based on gene
expression profiles. However, gene–disease association can manifest in many ways, such as alterations of gene expression,
genotype, and copy number; thus, an integrative approach combining multiple forms of evidence can more accurately
and comprehensively capture pathway associations. We have developed a single statistical framework, Gene Set Asso-
ciation Analysis (GSAA), that simultaneously measures genome-wide patterns of genetic variation and gene expression
variation to identify sets of genes enriched for differential expression and/or trait-associated genetic markers. Simulation
studies illustrate that joint analyses of genomic data increase the power to detect real associations when compared with
gene set methods that use only one genomic data type. The analysis of two human diseases, glioblastoma and Crohn’s
disease, detected abnormalities in previously identified disease-associated pathways, such as pathways related to PI3K
signaling, DNA damage response, and the activation of NFKB. In addition, GSAA predicted novel pathway associations,
for example, differential genetic and expression characteristics in genes from the ABC transporter family in glioblastoma
and from the HLA system in Crohn’s disease. These demonstrate that GSAA can help uncover biological pathways
underlying human diseases and complex traits.
[Supplemental material is available for this article.]
Dissecting the genetic and molecular mechanisms underlying com-
plex traits, including many diseases, is one of the key scientific goals
in the post-genomic era. In the past decade, genome-wide association
studies (GWAS) have emerged as one of the main strategies in finding
genetic variants associated with trait variation, and a large number of
genetic associations have been identified for a wide variety of com-
mon complex diseases as listed in the GWAS catalog (Hindorff et al.
2009) (http://www.genome.gov/gwastudies). Despite the enormous
success of these GWAS studies in uncovering important genetic ef-
fects, the identified single nucleotide polymorphisms (SNPs) explain
only a small proportion of the phenotypic variation, and the pre-
dictive power of these SNPs remains low for many complex dis-
eases (Manolio et al. 2009).
The majority of current GWAS analyze individual loci inde-
pendently to identify causal variants. These analyses have two re-
lated limitations. The first is that an initial GWA scan can yield a
large number of statistically significant loci that may include causal
variants as well as spurious associations, such as those that result
from cryptic population structure or other sources of error. It is also
difficult to distinguish causal variants from markers in strong link-
age disequilibrium (LD) with causal variants. A standard strategy to
minimize the number of false associations is to focus on the most
significant SNPs for biological validation. This gives rise to the sec-
ond limitation. Even if these significant SNPs correspond to causal
variants, they generally only account for a small proportion of the
phenotypic variation. These analyses are not ideal for diseases where
the common pattern of allelic architecture consists of potentially
hundreds of susceptibility loci that increase the risk of disease. Under
this model in which only a few of these variants have large effects
and most have small effects, the latter category may not be identified
by association analyses of individual variants (Wang et al. 2005).
To overcome these challenges of current GWAS approaches,
gene set/pathway association analyses have been developed that
identify variation in pathway activity or function associated with
trait variation. Compared with single-gene or single-SNP analyses,
set-based approaches can potentially (1) reduce the false positives
or decrease the uncertainty around causal genes or variants by in-
ferring associations over sets of biologically related genes; (2) fa-
cilitate interpretation of the results by providing insights into the
functional links between implicated genes or variants; and (3) un-
cover a significant biological effect distributed over multiple loci
even if changes in any individual locus have a small effect. Argu-
ably, this strategy is better suited to capture the allelic architectures
of complex diseases. Two dominant paradigms for gene set anal-
yses are association analyses based on gene expression profiles and
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those based on SNP genotypes. Numerous expression-based strate-
gies have been developed (Goeman et al. 2004; Boorsma et al. 2005;
Kim and Volsky 2005; Mansmann and Meister 2005; Subramanian
et al. 2005; Dinu et al. 2007; Maglietta et al. 2007; Newton et al. 2007;
Luo et al. 2009), and each method has its advantages, limitations,
and assumptions (for reviews and comparisons, see Khatri and
Draghici 2005; Allison et al. 2006; Goeman and Buhlmann 2007; Liu
et al. 2007; Abatangelo et al. 2009). More recently, a few methods
have been developed for pathway analyses using SNP data (Wang
et al. 2007; Holden et al. 2008; O’Dushlaine et al. 2009; Chen et al.
2010; De la Cruz et al. 2010; Peng et al. 2010; Zhong et al. 2010).
Gene set analyses based on a single data type, for example,
gene expression data or SNP data, have successfully revealed altered
cellular processes associated with complex diseases (Baranzini et al.
2009; Ooi et al. 2009; Liu et al. 2010; Zhang et al. 2010). However, an
integrative statistical framework and computational platform for
set-based analyses that can simultaneously leverage information
across both expression data and SNP data is still lacking. Valuable
associations may be discarded in single data type analyses. For
instance, genes with only genetic alterations are not considered in
gene set analyses based solely on expression data. Similarly, genes
with only expression changes cannot be captured by a purely SNP-
based approach. This may miss inferences of gene–disease associa-
tion that result, in part, from the complex interplay of genetic al-
terations and gene expression changes leading to the development
and progression of diseases. These issues create a need to integrate
both genetic and gene expression evidence into the association
analysis of gene sets. The observation that expression quantitative
trait loci (eQTLs) or eSNPs were more likely detected as disease
variants in association studies than SNPs not associated with ex-
pression differences (Gorlov et al. 2009; Nicolae et al. 2010) is ad-
ditional evidence supporting the need for methods integrating
gene expression analysis and SNP analysis.
In this study, we propose a novel integrative method called
Gene Set Association Analysis (GSAA) for the joint analysis of gene
expression and SNP data using a pathway-based strategy for more
accurate and comprehensive inference of associations. GSAA is based
on the idea of integrating evidence across multiple levels of analyses
into a single statistical framework to analyze genetic variation across
all SNPs mapped to genes and expression variation over all genes si-
multaneously. The model integrates these two types of genomic
information as overall evidence for gene set association analysis.
Using extensive simulation studies, we illustrated that GSAA
outperforms each of three gene set methods that use only one ge-
nomic data source and that joint analyses reduced the false dis-
covery rate (FDR) in all simulated scenarios and increased the power
in nearly all simulated scenarios. We further validated the ability of
GSAA to identify association signals in human disease using data
sets from glioblastoma and Crohn’s disease. We found significant
associations of well-known disease-associated pathways, such as
pathways related to PI3K signaling and DNA damage response in
glioblastoma and pathways involved in the activation of NFKB in
Crohn’s disease. These integrative analyses also revealed novel path-
way associations we did not find in single data analyses, for example,
aberrations in ABC transporter family in glioblastoma and in the
human leukocyte antigen (HLA) system in Crohn’s disease.
Java-based software implementing GSAA is freely available
at http://gsaa.unc.edu. The software includes a user-friendly and
straightforward graphical user interface and provides full support
for the visualization of results. In addition, we also provide a separate
module called gene set association analysis-SNP (GSAA-SNP) that
was used in this study and performs pathway-based analysis based
solely on SNP genotype data. The GSAA platform now supports the
gene set association analysis of all species with complete genome
sequences available in the Ensembl database (http://ensembl.org/).
Results
A summary of the multilevel model that was implemented via
GSAA is outlined in Figure 1 (for details, see Methods). The key steps
consist of (1) calculating gene level scores for differential expression
and genetic association, respectively (Fig. 1, Differential gene ex-
pression score, Single-SNP association score/SNP-set association
score); (2) combining the two gene level scores using a single metric
(Fig. 1, Gene association score); and (3) evaluating these combined
scores in terms of gene sets or pathways (Fig. 1, gene set/pathway
association test).
Simulation studies
We conducted a comprehensive simulation study to illustrate the
power of GSAA under various conditions of genetic association and
differential expression and to justify the use of certain summary sta-
tistics for data integration. These simulations were designed to eval-
uate two primary questions: (1) What is the relative performance and
what are the advantages of the various statistical summaries explored
to integrate evidence in our pathway-based approach? (2) Can we
reduce the FDR and increase the power of association tests by in-
tegrating expression and genotypic data into pathway-based analyses?
GSAA uses summary statistics to summarize evidence at two
distinct steps. The first occurs when evidence of differential ex-
pression is combined with evidence of genetic association at the
Figure 1. Overview of GSAA. Differential gene expression scores are
computed for each gene from gene expression profiles (left). Inde-
pendently, SNP set association scores for each gene are likewise computed
based on the SNPs assigned to the respective gene (right). The gene as-
sociation scores integrate evidence from both the expression signature
and the genotype signature for each gene. Finally, the pathway associa-
tion test identifies gene sets associated with samples of a single phenotype
by integrating evidence across genes in the gene sets.
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level of single genes (Fig. 1, gene association score). The second is
when this single gene evidence is aggregated across genes within
an a priori defined gene set (Fig. 1, gene set/pathway association
test). To combine expression and association evidence at the gene
level, we evaluated the following statistics (for details, see Methods):
a Z-score based sum statistic (zs), a statistic based on Fisher’s method
(fm), and a rank sum statistic (rs). To integrate evidence across genes,
we used a weighted Kolmogorov-Smirnov (K-S) statistic (ks). This
results in variations of GSAA indexed by these two statistics, for
example, GSAAzs-ks uses the Z-score-based sum statistic at the gene
level and the weighted K-S statistic at the gene set level. The varia-
tions of GSAA we compared were zs-ks, fm-ks, and rs-ks. We added to
these comparisons an SNP-based gene set association analysis called
GSAA-SNP (see Methods), the previously developed Gene Set En-
richment Analysis (GSEA) (Subramanian et al. 2005) that performs
expression based enrichment analysis, and a variant of GSEA we
implemented that ranks genes based on the absolute value of their
expression differences that we refer to as GSEAndes (see Methods).
We designed five scenarios in our simulation study to test how
each of the methods evaluated performed under varying magnitudes
and presence of signals in the SNP and expression data with respect to
case versus control samples. In each scenario, we simulated genotype
and expression data for 1000 genes and 100 gene sets. Only one of
100 defined genes sets contained causal genes. This ‘‘causal gene set’’
contained 16 genes of which a subset were genetically associated and
differentially expressed. The remaining 99 gene sets corresponded to
a null model and were composed of a random subset of the remaining
984 non-causal genes. Note that a non-causal gene may be assigned
to multiple gene sets by this design (for details, see Methods). The five
scenarios are distinguished by the degree and type of signal embed-
ded in the genes constituting the causal gene set:
S1: Eight of the 16 genes are both genetically associated with the
phenotype and differentially expressed with these eight genes
up-regulated in cases.
S2: Four genes are both genetically associated and differentially
expressed, all up-regulated in the cases. Four other genes are only
differentially expressed, all up-regulated in cases.
S3: Four genes are both genetically associated and differentially
expressed, all up-regulated in cases. Four other genes are only
genetically associated.
S4: Eight genes are both genetically associated and differentially
expressed, six of them up-regulated in cases and the other two
down-regulated in cases.
S5: Four genes are only up-regulated in cases. Four other genes are
only genetically associated.
In each scenario, the strength of association at the causal loci in the
SNP data is determined by the odds ratios at the loci where the odds
ratio is drawn independently from a uniform distribution (see
Methods). The extent of differential expression is determined by
the effect size at each gene in a regression model with the effect size
drawn independently from a uniform distribution (see Methods).
This process allows for the modeling of a spectrum of effect sizes at
the causal loci as well as of the differentially expressed genes.
As stated above, the two objectives of the simulation study
were, first, to select the summary statistic to use for integration across
genomic data sources at the single-gene level and, second, to quan-
titate the benefit of an integrative model. Results using the simulated
data described above for GSAA and for the three single data type
analyses—GSAA-SNP, GSEA, and GSEAndes—are reported in Table 1.
For these results, the odds ratio for simulating the genetic associ-
ation was drawn from a uniform distribution (U [1.1, 1.3]). Results
using U [1.2, 1.4] are shown in Supplemental Table S1. The average
P-value, FDR, and FWER for the causal gene set over 200 replicates
and the power of each method in each scenario are reported. The
P-value, FDR, and FWER were calculated based on 2000 permuta-
tions of phenotype labels. Power was calculated as the proportion
of replicates for which the P-value for the causal gene set was <0.05.
With respect to our first objective, these results show that when
combining information at the single gene level, the Z-score-based
sum statistic performs considerably better than the rank sum sta-
tistic and slightly better than the Fisher’s method statistic with re-
spect to the FDR and FWER (Table 1; Supplemental Table S1). In-
terestingly, the rank sum statistic tends to have the lowest power.
This may suggest that the loss of information when using only
Table 1. Simulation results based on scenarios S1–S5
GSAAzs-ks GSAAfm-ks GSAArs-ks
Scenario P-value FDR FWER Power P-value FDR FWER Power P-value FDR FWER Power
S1 0.00136 0.00861 0.00678 0.995 0.00226 0.01069 0.00989 0.99 0.02232 0.20798 0.20691 0.87
S2 0.00929 0.05686 0.05937 0.95 0.00988 0.05678 0.06230 0.97 0.07403 0.43896 0.47427 0.61
S3 0.00232 0.01158 0.01049 0.995 0.00521 0.02769 0.02620 0.99 0.06899 0.40380 0.42313 0.655
S4 0.00100 0.00378 0.00359 1 0.00151 0.00587 0.00567 1 0.02679 0.23876 0.25247 0.845
S5 0.01059 0.07656 0.07863 0.955 0.01431 0.10589 0.10882 0.94 0.13899 0.59330 0.65140 0.38
GSAA-SNP GSEA GSEAndes
Scenario P-value FDR FWER Power P-value FDR FWER Power P-value FDR FWER Power
S1 0.00300 0.08506 0.08966 0.985 0.00354 0.13129 0.12922 0.99 0.00526 0.32252 0.32704 0.975
S2 0.02956 0.36058 0.39286 0.88 0.00288 0.15532 0.15265 0.995 0.00566 0.35774 0.35181 0.97
S3 0.00300 0.08506 0.08966 0.985 0.05040 0.49751 0.51888 0.74 0.03596 0.48409 0.50091 0.8
S4 0.00300 0.08506 0.08966 0.985 0.08978 0.72820 0.80797 0.465 0.00378 0.31637 0.31944 0.985
S5 0.03866 0.45631 0.49498 0.795 0.04868 0.50246 0.53658 0.705 0.03313 0.44409 0.48971 0.82
Three versions of GSAA were evaluated where each varied the summary statistic used for combining genetic and gene expression evidence at the single
gene level: GSAAzs-ks, GSAAfm-ks, and GSAArs-ks. Also shown are results for GSAA-SNP, GSEA, and GSEAndes. For these simulations, the odds ratios for




rank information causes a decrease in power. In addition, we note
that Fisher’s method for combining P-values has limitations. It
treats large and small P-values asymmetrically and is asymmetri-
cally sensitive to small P-values compared with large P-values
(Whitlock 2005). This asymmetry could result in a bias in certain
conditions that may lead to worse overall performance.
As to our second objective, we evaluated the advantage of
using an integrative approach by comparing the FDR and power
for GSAAzs-ks and three single-source methods: GSAA-SNP, GSEA,
and GSEAndes. Our results indicate that GSAAzs-ks substantially
outperforms each of these three single data type analyses (Table 1;
Supplemental Table S1). Overall, FDRs from GSAAzs-ks are consis-
tently smaller than GSAA-SNP, GSEA, and GSEAndes in all simu-
lated scenarios. The power of GSAAzs-ks is also better than or equal
to those of single data type analyses in all simulated situations ex-
cept for scenario S2 under the odds ratio setting U [1.1, 1.3], in
which GSEA and GSEAndes is slightly better. Gene association
scores calculated using GSAAzs-ks are higher for genes with alter-
ations in both gene expression and genotype compared with genes
with a single type of alteration. As expected, GSAAzs-ks performs
better than single data type analyses when all or part of causal genes
contain both gene expression and genetic alterations (S1–S4).
GSAAzs-ks also shows increased ability to detect effects when
the gene set includes both types of alterations, but in which no
single gene simultaneously contains both types (S5). GSAA-SNP
performance decreases when fewer genes are associated with phe-
notype (S2 and S5), and both variants of GSEA suffer when fewer
genes are differentially regulated (S3 and S5). Interestingly, the
power of traditional GSEA decreases markedly when the causal
gene set contains both up-regulated and down-regulated genes
(S4), but GSEAndes still retains power similar to scenario S1 in this
case. Since both GSAA and GSEAndes use a non-directional dif-
ferential expression score, there was no loss of power when up-
regulation and down-regulation of genes coexist in the gene set.
Analyses of glioblastoma data
Human glioblastoma, the most common type of primary adult brain
cancer, was the first cancer targeted for analysis within The Cancer
Genome Atlas (TCGA) project. Several types of molecular data were
generated including gene expression and SNP genotype data as
well as DNA copy number and sequence data (Cancer Genome Atlas
Research Network 2008). We applied GSAAzs-ks, GSAA-SNP, GSEA,
and GSEAndes to these data using gene sets from the Molecular
Signatures Database (MSigDB) that included 357 canonical path-
ways (see Methods). We used GSAAzs-ks based on our simulations
that indicated that the Z-score-based data integration tends to have
the highest ability to detect effects of association. Full results are
shown in Supplemental Tables S2–S8. Consistent with previous
analyses using GSEA, we use a FDR cutoff of 0.25 (Subramanian et al.
2005). For these results, we have designated gene sets as being as-
sociated with the phenotypic class in which genes are up-regulated
overall, although in many gene sets there will be some genes that are
down-regulated in the assigned class. GSAAzs-ks identified 39 ca-
nonical pathways significantly associated with tumor samples with
FDR # 0.25 (Table 2; Supplemental Table S2).
Initial integrative pathway analyses carried out by TCGA using
sequence and DNA copy number data, but not SNP genotype data,
indicated that three major pathways are frequently altered in glio-
blastoma: RTK/RAS/PI3K signaling, p53 signaling, and RB signaling
(2008). Consistent with this, we identified multiple pathways in-
volved in different aspects of these three signaling pathways. Three
pathways (Table 2: G20, G21, G28) contain core components of
RTK/RAS/PI3K signaling (see Supplemental Table S2 for genes in
these pathways) with pathways G20 and G28 directly describing
PI3K/AKT signaling. PI3K acts as an upstream activator of AKT that
has pivotal roles in apoptosis, proliferation, and cell survival, and
alterations of genes in the PI3K/AKT pathway have been consid-
ered as causal forces underlying cancer (Osaki et al. 2004; Carnero
et al. 2008). Pathway G21 is involved in the activation of the EGFR
pathway. EGFR is reportedly overexpressed and mutated in a sig-
nificant proportion of glioblastoma (Heimberger et al. 2005).
Alterations in p53 and RB signaling are reflected by another
group of pathways: G8, G17, G22, G24, G25, and G29. These path-
ways are commensurate with a general oncogene-induced DNA
damage model for cancer development and progression uncovered
by several experimental studies (Kastan and Bartek 2004; Bartkova
et al. 2005; Gorgoulis et al. 2005; Venkitaraman 2005; Halazonetis
et al. 2008). The key contributors to the association of these path-
ways contain the core genes involved in checkpoint response to
DNA damage such as TP53, CHEK2 (also called CHK2), and ATM
(Supplemental Table S2). In addition, the DNA damage model in-
dicates the involvement of apoptosis and DNA replication in the
oncogenesis. A considerable number of significant pathways in
GSAA analysis are also related to apoptosis (G1, G2, G5, G11, G12,
G14, G20, G27, G28, G35, G37, G39) and DNA replication (G26).
In addition to aberrations in these well-known signaling path-
ways, GSAA analysis also suggested a role for the family of ATP-
binding cassette (ABC) transporters, the third-ranked pathway (G3).
Gene expression profiles of many ABC transporter genes were sig-
nificantly altered in tumor samples. Some genes, such as ABCB7
and ABCC4, were up-regulated, while others, for example, ABCC8
and ABCG4, were down-regulated. Significantly associated geno-
mic variants were found in several of these genes including ABCB7
rs6647618: p = 1.0 3 104) and ABCC4 (rs7324277: p = 1.0 3 104).
Normal and cancer stem cells have been shown to express high
levels of ABC transporters that are normally inactive in more mature
cells, and the overexpression of specific ATP transporters has been
found to significantly affect the chemoresistance phenotype of
cancer cells (Bronger et al. 2005; Bleau et al. 2009).
GSAA analysis also suggests a connection between the coagu-
lation system and glioblastoma, represented by the signaling path-
way involved in platelet activation (G4) and the intrinsic pro-
thrombin activation pathway (G13). Patients with cancer, especially
glioblastoma, have been shown to have increased risk for throm-
bosis, characterized by alterations in normal blood flow, injury to
the vascular endothelium, and alterations in the constitution of
blood (Lyman and Khorana 2009; Reynes et al. 2010). Glioblastoma
cells have also been found to become both procoagulant and hy-
persensitive to TF/PAR-mediated signaling. The expression of EGFR
and the most common EGFR mutant, EGFRvIII, is thought to drive
this transformation (Magnus et al. 2010). In addition, our analysis
indicated that the coagulation factor receptor F2R (also called
PAR1) is the most significantly up-regulated gene in glioblastoma
samples. F2R is also significantly associated in the SNP-based test
(rs2227753: p = 1.0 3 104). F2R is functional in glioblastoma cells
and can mediate anti-apoptotic signaling in the nervous system
(Guo et al. 2004; Junge et al. 2004). Another pathway, the VEGF
pathway (G19), is also related to blood flow being involved in tu-
mor angiogenesis (Plate et al. 1994; Saharinen et al. 2011).
Two identified gene sets are related to other cancers, namely,
bladder cancer (G32) and myeloid leukemia (G38), and have
common components with other cancer types. Several pathways
are involved in sugar metabolism (G16, G18, G33, G36).
Integrative association analysis of gene sets
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We also investigated the 83 pathways associated with normal
samples at FDR # 0.25 (Supplemental Table S3). Perturbations in
calcium-mediated signal transduction pathways may be involved
in the pathogenesis of glioblastoma since the top three pathways
were calcineurin-mediated pathways and 26 of the 83 significant
pathways were calcium/calmodulin-dependent. The expression
level of catalytic subunit A of calcineurin (PPP3CA) and some genes
in the families of calmodulins (CALM) and calcium/calmodulin-
dependent protein kinases (CAMK), for example, CALM1, CALM2,
CALM3, CAMK2A, and CAMK2B, were down-regulated in tumor
tissues. Some genes also include statistically significant genomic
variants, such as PPP3CA (rs12647627: p = 1.0 3 104) and CALM1
(rs2300500: p = 1.0 3 104). It has been shown that a high level of
activity of calcineurin predisposes neuronal cells to apoptosis (Asai
et al. 1999; Wang et al. 1999). Calcium-mediated signaling also has
a role in the regulation of the cell cycle (Baksh et al. 2000; Kahl and
Means 2003). Interestingly, a gene set defined based on genes in-
volved in glioma (G69) is associated with normal samples. We
noticed that this pathway, unlike other cancer pathways, contains
many CALMs and CAMKs that were down-regulated in tumor
tissues, although other genes, such as EGFR and TP53, were up-
regulated (see Supplemental Table S3 for genes in this pathway).
This may explain why this pathway was more associated with
normal samples and supports the connection between calcium
processing and glioblastoma. Other top pathways were related to
the release of neurotransmitters such as glutamate (G1, G6) and
ATPase signaling (G16, G19, G22, G31). These results suggest
that these particular processes were down-regulated in diseased
tissues.
Neither GSEA nor GSAA-SNP identified significant pathways
associated with tumor samples at FDR # 0.25 (Supplemental Tables
S4, S6). However, in both GSEA and GSAA-SNP, the 10 most sig-
nificant pathways included ones related to cell cycle checkpoints
and the coagulation system. GSEA also reported pathways involved
in apoptosis and DNA replication, while PI3K/AKT signaling path-
ways were highly ranked by GSAA-SNP. Similar pathways as those
found significantly associated with normal samples by GSAA were
likewise identified by GSEA (Supplemental Tables S3, S5). GSEAndes
Table 2. Significant pathways associated with glioblastoma tumor samples (FDR # 0.25)
Index Gene set name P-value FDR Function
G1 RELAPATHWAY 0.0010 0.0463 Proliferation, migration and apoptosis
G2 CERAMIDEPATHWAY 0.0006 0.0676 Apoptosis, cellular differentiation, proliferation
G3 HSA02010 ABC TRANSPORTERS_GENERAL 0.0036 0.1247 ATP binding
G4 SPPAPATHWAY 0.0002 0.1305 Thrombin signaling, blood coagulation
G5 NFKBPATHWAY 0.0109 0.1361 Proliferation, migration, apoptosis
G6 HCMVPATHWAY 0.0118 0.1505 Proliferation, viral replication
G7 TOLLPATHWAY 0.0083 0.1555 Immune response, proliferation
G8 G2PATHWAY 0.0054 0.1658 Cell cycle checkpoints, DNA damage response
G9 INTEGRINPATHWAY 0.0043 0.1732 Cellular shape, mobility, cell cycle
G10 CARM ERPATHWAY 0.0060 0.1734 Activation of transcriptional factors,
regulation of estrogen receptor
G11 TNFR1PATHWAY 0.0102 0.1830 Apoptosis
G12 FASPATHWAY 0.0140 0.1834 Apoptosis
G13 INTRINSICPATHWAY 0.0287 0.1858 Thrombin signaling, blood coagulation
G14 STRESSPATHWAY 0.0052 0.1931 Apoptosis
G15 HSA05040 HUNTINGTONS DISEASE 0.0078 0.1932 Huntington disease
G16 HSA00531 GLYCOSAMINOGLYCAN
DEGRADATION
0.0499 0.1932 Glycosaminoglycan degradation
G17 ATMPATHWAY 0.0289 0.1952 Cell cycle checkpoints, DNA damage response
G18 FRUCTOSE AND MANNOSE METABOLISM 0.0288 0.1998 Fructose and mannose metabolism
G19 VEGFPATHWAY 0.0084 0.2031 Angiogenesis, blood vessel formation
G20 SIG PIP3 SIGNALING IN B LYMPHOCYTES 0.0223 0.2065 PI3K/AKT signaling, apoptosis, proliferation
G21 CARDIACEGFPATHWAY 0.0125 0.2106 EGFR signaling
G22 CELLCYCLEPATHWAY 0.0332 0.2106 Cell cycle checkpoints, DNA damage response
G23 ST ERK1 ERK2 MAPK PATHWAY 0.0172 0.2150 ERK1/ERK2 MAPK signaling
G24 RACCYCDPATHWAY 0.0281 0.2152 Cell cycle
G25 CELL CYCLE KEGG 0.0722 0.2164 Cell cycle checkpoints, DNA damage response
G26 TELPATHWAY 0.0590 0.2252 DNA replication, cell division
G27 ST FAS SIGNALING PATHWAY 0.0177 0.2310 Apoptosis
G28 AKTPATHWAY 0.0510 0.2312 PI3K/AKT signaling, apoptosis, proliferation
G29 ARFPATHWAY 0.0746 0.2334 Cell cycle checkpoints, DNA damage response
G30 HSA04120 UBIQUITIN MEDIATED
PROTEOLYSIS
0.0412 0.2351 Proteolysis
G31 IL7PATHWAY 0.1139 0.2388 B- and T-cell development
G32 HSA05219 BLADDER CANCER 0.0217 0.2403 Bladder cancer
G33 HSA00051 FRUCTOSE AND MANNOSE
METABOLISM
0.0416 0.2404 Fructose and mannose metabolism
G34 INTEGRIN MEDIATED CELL ADHESION KEGG 0.0108 0.2411 Cellular shape, mobility, cell cycle
G35 TNFR2PATHWAY 0.0722 0.2444 Apoptosis, proliferation
G36 HSA01032 GLYCAN STRUCTURES DEGRADATION 0.0886 0.2453 Glycan degradation
G37 ST P38 MAPK PATHWAY 0.0275 0.2489 p38 MAPK signaling, proliferation,
differentiation, apoptosis
G38 HSA05220 CHRONIC MYELOID LEUKEMIA 0.0119 0.2495 Myeloid leukemia
G39 SPRYPATHWAY 0.0947 0.2497 Proliferation, differentiation, apoptosis




did not identify any pathways as significant in either direction
(Supplemental Tables S7, S8).
Analyses of Crohn’s disease data
To explore the performance of GSAA within the context of a non-
cancer complex disease, we applied GSAAzs-ks, GSAA-SNP, GSEA,
and GSEAndes to previously published gene expression and SNP
genotype data from patients with and without Crohn’s disease
(CD). As before, MSigDB canonical pathways (352) were used for
this analysis. Full results are shown in Supplemental Tables S9–S15.
GSAA analysis identified 12 canonical pathways significantly as-
sociated with case samples at FDR # 0.25 (Table 3; Supplemental
Table S9).
Proteasome activity was found to be highly associated with
disease because the fifth and eleventh most significant pathways
were directly related to the proteasome complex. Recent studies have
demonstrated that the transcription factor NFKB is a key regulator of
epithelial integrity and intestinal immune homeostasis (Ben-Neriah
and Schmidt-Supprian 2007; Nenci et al. 2007; Zaph et al. 2007;
Atreya et al. 2008; Spehlmann and Eckmann 2009). Deficiency in
or hyperactivation of NFKB is one of the core mechanisms leading
to chronic inflammatory bowel disease (IBD). NFKB signaling is
primarily regulated by inhibitory IkB proteins and the IkB kinase
complex. Proteasomes play a crucial role in the degradation of in-
hibitory IkB proteins and the activation of NFKB (Mattson and
Meffert 2006; Visekruna et al. 2006; Atreya et al. 2008). We found
that most of the proteasome-related genes were up-regulated in
disease samples including PSMB8 (also called LMP7) and PSMB9
(also called LMP2). PSMB9 also contains a significant genomic
variant (rs20547: p = 0.0115). PSMB8 and PSMB9 are two subunits
of the immunoproteasome encoded by the HLA region and are
required for the degradation of phosphorylated IkB proteins and
for processing of the NFKB precursor (Hayashi and Faustman 2000;
Visekruna et al. 2006). Overexpression of immunoproteasomes in
the inflamed intestine of CD patients has been observed in multiple
studies and has been found correlated to the excessive NFKB acti-
vation (Visekruna et al. 2006, 2009a,b). In addition, there is in-
creasing evidence that a bacterial or viral infection and the host
reaction to that infection play an important role in the onset of
Crohn’s disease (Irving and Gibson 2008). Immunoproteasomes
can be induced and replace standard proteasomes quickly in re-
sponse to the viral infection (Yewdell 2005). This process involves
the rapid expression of immunoproteasomes, possibly explaining
the relevance of two high-ranked pathways related to aminoacyl-
tRNA biosynthesis (Table 3).
A gene set encapsulating key genes underlying type I diabetes
(T1D) ranked third among canonical pathways. This pathway in-
cludes a large number of genes belonging to the HLA system (see
Supplemental Table S9 for genes in this pathway). The HLA system
encodes cell surface molecules specialized to present antigenic
peptides to the T-cell receptor (TCR) on T cells and plays a critical
role in the immune system and autoimmunity (Benacerraf 1981;
Fernando et al. 2008). It has been shown that T1D and inflam-
matory bowel disease share common susceptibility pathways (Wang
et al. 2010). Multiple loci within HLA genomic region have been
reported to be associated with CD (Forcione et al. 1996; Reinshagen
et al. 1996; Lombardi et al. 2001; Newman et al. 2004), and addi-
tional susceptibility loci may remain undiscovered.
GSAA found five pathways, in addition to the T1D pathway
(G3), that are relevant to immune response (G1, G4, G6, G8, G9).
Thrombopoietin signaling (G10) was also identified and has been
previously reported to be disturbed in CD (Kapsoritakis et al. 2000).
Sixteen pathways were significantly associated with control
samples at FDR # 0.25 (Supplemental Table S10). Seven (G1, G2, G3,
G4, G7, G8, G10) are related to G-protein-coupled receptor (GPCR)
signaling or PI3K/AKT signaling. GPCRs are upstream regulators
of PI3K/AKT signaling. PI3K has important roles in lymphocyte
development, differentiation, and activation (Okkenhaug and
Vanhaesebroeck 2003; Okkenhaug and Fruman 2010). Multiple
studies have shown the correlation between the PI3K pathway and
IBD (Fukao and Koyasu 2003; Zhao et al. 2008).
GSEA analysis identified 17 pathways significantly associated
with case samples at FDR # 0.25 (Supplemental Table S11). Except
for two proteasome-related pathways (G4, G8), GSEA identified
multiple additional pathways involving the activation of NFKB.
The RelA (G3) and NFKB (G14) pathways describe NFKB signaling.
The NTHi pathway (G17) describes the induction of an inflam-
matory response through activation of NFKB triggered by bacterial
infection. Six pathways (G1, G5, G6, G7, G13, G17) contain genes
that participate in the immune system or inflammatory response.
In addition, another identified pathway (G11) is responsible for
the activation of matrix metalloproteinases and the degradation
of the extracellular matrix. It has been shown that TNF mediated
Table 3. Significant pathways associated with case samples (FDR # 0.25)
Index Gene set name P-value FDR Function
G1 SIG BCR SIGNALING PATHWAY 0.0004 0.0231 Immune response
G2 AMINOACYL TRNA BIOSYNTHESIS 0.0014 0.0239 tRNA biosynthesis
G3 HSA04940 TYPE I DIABETES MELLITUS 0.0008 0.0294 Autoimmunity, immune response,
inflammation
G4 ST G ALPHA I PATHWAY 0.0000 0.0306 Chemotaxis, G-protein signaling,
immune response
G5 PROTEASOME 0.0586 0.0357 Activation of NFKB
G6 ST DICTYOSTELIUM DISCOIDEUM CAMP
CHEMOTAXIS PATHWAY
0.0000 0.0389 Chemotaxis, G-protein signaling,
immune response
G7 HSA00970 AMINOACYL TRNA BIOSYNTHESIS 0.0085 0.0476 tRNA biosynthesis
G8 SA B CELL RECEPTOR COMPLEXES 0.0008 0.0675 Immune response
G9 HSA04514 CELL ADHESION MOLECULES 0.0000 0.0744 Immune response, inflammation
G10 TPOPATHWAY 0.0041 0.1203 Thrombopoietin Signaling
G11 PROTEASOMEPATHWAY 0.0715 0.1374 Activation of NFKB
G12 HSA00565 ETHER LIPID METABOLISM 0.0136 0.1824 Ether lipid metabolism
For full results, see Supplemental Table S9.
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up-regulation of matrix metalloproteinases results in severe dam-
age of the extracellular matrix and mucosal degradation (Pallone and
Monteleone 2001; Atreya et al. 2008). An altered apoptosis pathway
(G10) may contribute to inappropriate T-cell accumulation and sub-
sequently chronic inflammation (Ina et al. 1999). Only one path-
way associated with control samples reached significance in the
gene expression analysis of GSEA (Supplemental Table S12). GSAA-
SNP identified seven significant pathways, of which four (G1, G2,
G5, G7) are related to PI3K signaling (Supplemental Table S13).
GSEAndes identified four significant pathways of which the top
three were proteasome pathways (Supplemental Table S14). The
fourth gene set is related to the activation of matrix metal-
loproteinases also suggested by GSEA. No pathways associated
with normal samples reached significance in the GSEAndes anal-
ysis (Supplemental Table S15).
Discussion
Genome-wide gene expression profiling and genotyping offer
unparalleled opportunities to elucidate the underlying mechanisms
of complex traits or diseases. In this study, we developed a novel sta-
tistical framework that simultaneously integrates gene expression
data and genotype data into genome-wide association analysis of
biological pathways or gene sets. Combining evidence from these
two genomic data sources facilitates identification of genes with dif-
ferential gene expression, genetic alterations, or both characteristics
that are associated with phenotypic traits. Results from our simula-
tion study and the analyses of glioblastoma and Crohn’s disease data
showed that GSAA captured association signals that occur in either
type of genomic data as well as across both genomic data sources.
Many functionally relevant variants that are deleterious have
minor allele frequencies of <5% and therefore are not well repre-
sented on SNP chips used in GWAS. However, new sequencing
technologies are enabling the better identification of both com-
mon and rare variants. An area of future development is to adapt
GSAA to detect associations of both common variants and rare
variants in gene sets by integrating sequence analysis and gene
expression analysis. There is no conceptual difference between
using sequence data and SNP data in our method. GSAA is well
suited to capture concordant association signals over a gene set or
multiple loci even if the association information carried by each
gene or locus is weak. This is a key strength of GSAA since current
research has shown that most complex human diseases are asso-
ciated with the presence of multiple common or rare variants, each
with a low marginal effect, and not simply a few common variants
(Kryukov et al. 2007; Gorlov et al. 2008; Robinson 2010). Similarly,
other genomic data such as copy number variation, methylation,
and microRNA expression will be explored as inputs to GSAA.
GSAA requires a mapping of SNPs to genes. Currently, it is not
known exactly what genomic regions affect the function of each
particular gene. In our analyses, to each gene we assigned SNPs that
were within the region spanning 1 kb upstream of the TSS to the end
of the transcribed bases. We know that for many cases, this may not
include variants in distal regulatory regions hundreds of kilobases
away that influence gene expression levels, but it should include
those in the core and proximal promoter regions and part of those in
the distal promoter (Bortoluzzi et al. 2005). This mapping can in-
clude information about distal regulatory variants if they are in LD
with those included in our mapping intervals or if they are within
the mapping intervals of other genes in the gene set. In two previous
studies (Wang et al. 2007; Peng et al. 2010), one mapped SNPs to the
closest gene, while another used all SNPs within a gene to represent
that gene. GSAA software provides users the ability to define their
own SNP mapping criteria by specifying how many base pairs up-
stream of and/or downstream from a gene a SNP must be included.
Hopefully, the current influx of functional genomic data, especially
chromatin data, will eventually allow more accurate mappings.
The optimal way to assess the joint contribution of multiple
SNPs mapped to the same gene in association analyses is un-
known. The region of association for a gene may harbor only one
risk variant or may harbor multiple risk variants that independently
contribute to the overall association signal. Compared to test sta-
tistics that combine correlation scores or P-values across all SNPs, we
believe that the maximum statistic we used can more effectively
eliminate the negative effects of correlation structure between SNPs
and differences in SNP set size on association inference. The maxi-
mum statistic should be the best way to measure association signals
when the gene region only contains a single risk variant, but con-
tain multiple markers in strong LD with the risk variant that may
artificially inflate the association. However, this statistic cannot
accurately capture the overall association information when mul-
tiple independent risk variants coexist. GSAA would benefit by the
development of new algorithms that more effectively assess joint
contributions of SNPs to the trait variation. Given its modular
framework, new algorithms like these could be easily incorporated.
Gene set association analysis takes advantage of prior knowl-
edge of biological pathways. Operating at the pathway level aids in
interpreting results, especially across different experimental plat-
forms or strategies. However, this creates a dependence on a priori
knowledge. Inaccurate or incomplete information about these path-
ways may lead to inaccurate association inferences. With the ac-
cumulation of our knowledge on biological processes, pathway
annotations are becoming increasingly more accurate, which will
continue to increase the power of gene set association tests.
In summary, we report here a novel statistical framework that
is capable of effectively identifying the biological pathways or gene
sets associated with complex traits or diseases by integrating ge-
netic and gene expression evidence into genome-wide association
analysis of gene sets. Compared with gene set methods that use only
one genomic data type, our proposed method reduces the FDR in all
simulated scenarios and increases the power in nearly all simulated
scenarios. In real settings, it not only confirmed the associations of
well-known pathways but also provided new insights into the eti-
ology of disease.
Methods
Gene set association analysis
GSAA is based on multiple layers of association tests. The advan-
tage of a multi-layer approach is that evidence for an association
signal is aggregated from individual SNPs to individual genes to
gene sets. See Figure 1 for a graphical overview of the method. The
methodology formulated here is for the case in which samples be-
long to one of two phenotypic classes. This multi-level procedure
consists of five individual calculations: (1) computation of a differ-
ential gene expression score; (2) computation of a single-SNP asso-
ciation score; (3) computation of a SNP set association score; (4)
computation of a gene association score; and (5) a gene set associ-
ation test. The following describes each of these in detail.
Differential gene expression score
The differential expression score reflects the degree to which a gene
is differentially expressed between two phenotypic classes. It can




test statistic used is the difference of the class means scaled by the
standard deviation. The absolute magnitude of the statistic in-
dicates the strength of the correlation between the gene expression
profile and the phenotype, and the sign indicates the direction of
this correlation. In our software, we provide five different statistics
that can be used to calculate this differential expression score,
similar to GSEA (for more details, see Supplemental Document S1).
Single-SNP association score
Five different methods to calculate single-SNP association scores
are provided in our software: a genotype-based x2 statistic; an allele-
based x2 statistic; a statistic based on frequency differences in major/
minor alleles between the two classes; and two statistics extended
from genotype-based and allele-based x2 statistics, respectively (for
more details, see Supplemental Document S1). Other suitable test
statistics for the categorical phenotypes can be used. The results
described in this paper used the allele-based x2 statistic because it
had greater power than genotype-based x2 statistic for our simulated
SNP data that were based on an additive model (data not shown).
SNP set association score
Genotype data are complicated to analyze in gene-focused analy-
ses because there is not a standard mapping of SNPs to genes and
multiple SNPs can cover each gene and its regulatory region. To
assign SNPs to genes, we define a genomic interval encompassing
each gene and some specified number of bases upstream of and
downstream from the transcribed region. All SNPs within this in-
terval are used to represent the gene. Given these SNPs, we calculate
an SNP set association score for a gene using a maximum statistic.
The maximum statistic is the maximum single-SNP score over all
the SNPs assigned to the gene. This idea of selecting the maximum
score or minimum P-value is an example of a minP procedure used
in resampling-based multiple testing (Westfall and Young 1993).
Gene association score
The differential gene expression score and SNP set association score
for each gene are combined to generate a single gene association
score. This composite correlation integrates evidence for association
across the gene expression and SNP data. The differential gene ex-
pression scores used by GSEA (Subramanian et al. 2005) have direc-
tionality: positive values indicate greater expression in class 1, while
negative values indicate greater expression in class 2; therefore, the
weighted K-S test used in GSEA analysis may only capture differ-
ential expression signals from one direction. However, genes in the
same pathway are not always differentially expressed in the same
direction. Some pathways may contain both up-regulated and down-
regulated genes associated with the disease condition because there
exist feedback loops in some pathways, such as p53 pathway (Harris
and Levine 2005), where the increase in expression of one gene leads
to the increased expression of some genes but the decreased expres-
sion of others. The directionality derived from the SNP-based test is
not biologically meaningful because for each locus it is not known
which allele is actually associated with disease. For the SNP set asso-
ciation scores, we do not know the directionality.
Therefore, we take the absolute values of the differential gene
expression scores before data integration in order to capture both up-
regulation and down-regulation in pathways and to be consistent
with the form of SNP set association scores. Directionality is then
resolved at the gene set association test step below. In GSAA, three
methods are used to integrate the evidence from gene expression
analysis and SNP analysis to produce gene association scores.
Z-score sum
For each differential expression score or SNP set association
score, we first generate its null distribution by a phenotype-based
permutation procedure. Then we standardize these scores by the
mean and standard deviation of its null distribution. More spe-
cifically, suppose fe1; . . . ; eNg are the absolute values of differential
expression scores for N genes and fs1; . . . ; sNg are the SNP set as-
sociation scores for the same genes. The standard expression scores





and the standard SNP set association scores fzs1; . . . ; zsNg for the





where ðme;msÞ and ðse;ssÞ are the means and standard deviations of
the null distributions corresponding to ei and si, respectively. This
transformation brings the scores from different statistical tests or
on different scales onto a common scale so that these scores are
directly comparable with each other. The Z-score transformation
results in both positive values and negative values. Negative scores
indicate a lack of association. For convenience, we shift all these
scores to be positive by adding a constant c that is the absolute
value of the most negative score across all standard gene expres-
sion scores and standard SNP set association scores. The addition of
this constant transforms all negative standard gene expression
scores and standard SNP set association scores to positive scores
without changing the shapes of their distributions, particularly the
right tail, and has no meaningful effect on the subsequent analysis.
The gene association scores are the sum of these standard
scores gi = ðzei + cÞ+ ðzsi + cÞ.
Fisher’s method
For each differential gene expression score and SNP set association
score, we first generate its null distribution by a phenotype-based
permutation procedure, and then we estimate its P-value by com-
paring the score with its null distribution. Fisher’s method (Fisher
1932; Peng et al. 2010), also known as Fisher’s combined probability
test, is used to combine P-values from the expression-based test and
the SNP-based test to produce the integrative gene association score:




where K is the number of independent tests, in this case K = 2,
namely, expression-based test and SNP-based test, and pij is the
P-value for gene i in test j.
Rank sum
For each differential expression score or SNP set association score,
we first generate its null distribution by a phenotype-based per-
mutation procedure, and then we transform every score and its
corresponding null scores into ranks. Tied values are assigned
the average of the applicable ranks. For example, (2, 5, 6, 5) is
ranked as (1, 2.5, 4, 2.5). Gene association scores are then
computed as
gi = rei + rsi;
where rei and rsi are the ranks of gene i in the expression-based test
and SNP-based test, respectively.
Gene set association test
Given the gene association scores, we use a weighted Kolmogorov-
Smirnov (K-S) test to determine which gene sets have the greatest
combined evidence for association with the given phenotype. Es-
sentially, the weighted K-S test determines for each gene set
whether the genes belonging to that gene set are preferentially
near the top of the ranked ordered list based on gene association
scores. More formally, given a particular gene set S including H
genes and the rank ordered gene association scores fg1; . . . ; gNg for
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all genes in the expression data set, a running association score
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j gj jIðj 2 SÞ;
where Iðj 2 SÞ is an indicator variable that is one if the jth gene in
the rank ordered list is in gene set S and is otherwise zero. Similarly,
Iðj =2 SÞ takes the value of zero if the jth gene is in the gene set and is
otherwise one. The gene set association score, ASðSÞ, is the maxi-
mum deviation from zero of the running association score over the
positions i = 1; . . . ;N
ASðSÞ+ = max
i = 1;...;N
½RASSðiÞ; ASðSÞ = min
i = 1;...;N
½RASSðiÞ:
Finally, if jASðSÞ+j > jASðSÞj then the final gene set association score
ASðSÞ= ASðSÞ+, otherwise, ASðSÞ= ASðSÞ.
The gene association scores we used lack directionality, so a
negative AS(S) means that there is no association between the gene
set and the phenotype. We here set AS(S) = 0.0001 if AS(S) < 0 so
that negative AS scores will not confuse the following assign-
ment of the direction. One advantage for the standard GSEA analysis
is that its association score suggests the direction of an association.
In the K-S test used by GSAA to calculate the integrative gene set
association score, we aim to capture both up-regulated and down-
regulated genes in a gene set, so we do not assign directionality at
this point. Instead, we perform an additional K-S test based solely on
the directed differential gene expression scores to get a correspond-
ing expression-based association score (EAS) for each gene set. We
impose directionality on the integrative AS based on the sign of the
EAS for the same gene set, ASðSÞ = ASðSÞ3 signðEASðSÞÞ.
In GSAA, we integrate gene expression information and ge-
notype information at the gene level. However, some genes may
not have associated SNPs. For these genes, the gene association score
is just derived from the expression-based test. To account for possible
heterogeneity of information at each gene locus, we standardize the
original gene association score by the mean and standard deviations
of its null distribution using the same method as we used to calculate
the standard expression score before performing the K-S test.
The absolute magnitude of the AS score indicates the strength
of the association between the gene set and the phenotype, and
the sign indicates which phenotypic class the gene set is associated
with. Finally, a normalized association score (NAS) for each gene
set is calculated to adjust for difference in gene set size. Similar to
GSEA, we use a mean-based method and normalize the positive
and negative scores separately.
Assessment of statistical significance and adjustment for multiple
hypothesis testing
We assess the statistical significance of the gene set association score
and adjust for multiple hypothesis testing based on a phenotype-
based permutation procedure. This procedure preserves LD struc-
ture in SNP data and gene–gene correlation structure in gene ex-
pression data. A nominal P-value is calculated relative to a null
distribution generated by shuffling the phenotypic class labels and
recalculating the gene set association score many times. If the gene
expression and SNP data come from the same samples, i.e., from
matched data, GSAA will perform better. Since it may be difficult to
obtain matched genomic data and to be able to use GSAA on
existing GWA and gene expression data that may not be matched,
we designed GSAA to allow for both matched and unmatched data.
When the data are matched, permutations for the expression-based
test and SNP-based test are not independent, and GSAA uses the
same permutation template for both. This can result in greater
power to identify real associations.
We use the false discovery rate (FDR) and the family-wise error
rate (FWER) based on the normalized gene set association scores to
correct for multiple hypothesis testing and to control the pro-
portion of false positives below a certain threshold. Given m gene
sets fS1; . . . ; Smg and label permutations p = 1; . . . ;P, the FDR for
each gene set Si with NASðSiÞ $ 0 is computed as
FDRðSiÞ
=
% of NASðSj;pÞ+ $ NASðSiÞ for j = 1; . . . ;m and p = 1; . . . ;P
% of NASðSjÞ+ $ NASðSiÞ for j = 1; . . . ;m
;
If NASðSiÞ< 0, the FDR is computed as
FDRðSiÞ
=
% of NASðSj;pÞ # NASðSiÞ for j = 1; . . . ;m and p = 1; . . . ;P
% of NASðSjÞ # NASðSiÞ for j = 1; . . . ;m
;
where NASðSj;pÞ is the normalized association score for gene set j
with label permutation p. NASðSj;pÞ+ and NASðSj;pÞ denote
positive and negative NASðSj;pÞ, respectively. NASðSjÞ is the nor-
malized association score for gene set j. NASðSjÞ+, NASðSjÞ denote
positive and negative NASðSjÞ, respectively.
The FWER for a gene set Si with NASðSiÞ $ 0 is computed as
FWERðSiÞ= % of ½maxj = 1;...;m½NASðSj;pÞ+ $ NASðSiÞ for p = 1; . . . ;P:
If NASðSiÞ< 0, the FDR is computed as
FWERðSiÞ= % of½minj = 1;...;m½NASðSj;pÞ # NASðSiÞ for p = 1; . . . ;P:
Computational efficiency of GSAA
With respect to computational efficiency, GSAA took ;0.9 h and
4 h for the analyses of glioblastoma data and Crohn’s disease data,
respectively, using one computational node with eight processors
(Intel Xeon CPU E5520 @ 2.27 GHz). It only took ;3.5 min for the
simulated data sets.
Gene set association analysis-SNP (GSAA-SNP)
GSAA-SNP was created to perform gene set association analysis
based solely on SNP data. In GSAA-SNP, we remove the module of
the differential expression test in GSAAzs-ks and use the original
SNP set association score as the gene association score. Otherwise,
it is the same as GSAAzs-ks.
Gene set enrichment analysis based on non-directional differential
expression scores (GSEAndes)
Both GSAA and GSAA-SNP are based on the non-directional asso-
ciation analysis at the gene level. To compare them with the GSEA
more fairly, we created GSEAndes. GSEAndes is an extension of the
original GSEA software and also an expression-based version of
GSAAzs-ks. In GSEAndes, we remove the two modules of single-
SNP association test and SNP set association test in GSAAzs-ks and
use the original differential expression score as the gene associa-
tion score. Otherwise, it is the same as GSAAzs-ks.
Generation of simulated data
We generated simulated gene expression data and SNP genotype
data to study the power of various integrative methods and single-
source methods. Modeling a case-control setting, we simulated 200





For each simulation we generated 100 gene sets. Only the first
gene set (causal gene set) included risk genes. We randomly chose
a pathway, P53PATHWAY, that contains 16 genes from the Molec-
ular Signatures Database (MSigDB, http://www.broadinstitute.org/
gsea/msigdb/index.jsp) as a prototype to simulate the causal gene set.
The gene expression and genotype information of P53PATHWAY
were obtained from the glioblastoma data generated through The
Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov) pro-
ject. The remaining 99 gene sets were simulated from null models,
namely, none of the genes in these gene sets were associated with the
phenotype of interest with respect to gene expression profiles or
genotypes. The sizes of null gene sets were randomly drawn from
U[15, 30]. Genes within null gene sets were randomly drawn from
a pool of 984 non-causal genes.
SNP data
Each simulated SNP data set included 1000 genes, each gene with
one genotyped SNP for a total of 1000 SNPs. Some of these SNPs were
considered causally related to the phenotype of interest. We simu-
lated the causal SNPs in the causal gene set based on the genotype
information of P53PATHWAY. We first assigned SNPs that were
within the region 1 kb upstream of the transcription start site (TSS) to
the end of the transcribed bases to each gene in the P53PATHWAY,
then we removed SNPs with minor allele frequency (MAF) <0.05
and chose the SNP with the highest score in the x2 test as the tag
SNP of the gene. We set the allele frequencies of causal SNPs in the
simulated causal gene set the same as the allele frequencies of
corresponding tag SNPs in the P53PATHWAY. The heterozygote
odds ratio for each causal SNP was generated from U[1.1, 1.3] and
U[1.2, 1.4], respectively. We used an additive disease model for the
causal loci, and the disease prevalence was set to 0.02. We drew allele
frequencies from a Beta distribution, Beta(0.1, 0.1), for null SNPs
with no association with the phenotype based on the approxima-
tion for the unconditional distribution of allele frequencies in the
HapMap populations stated in Coram and Tang (2007). Based on
these parameter settings, the genotype data were generated by
PLINK (Purcell et al. 2007) (http://pngu.mgh.harvard.edu/purcell/
plink/). We then assigned the case-control status based on the model
logitfPrðYj = 1Þg= +Ni = 1 xGji bi + ej;
where N is the number of causal SNPs in the causal gene set. xGji
denotes the coding of the genotype at causal SNP i for sample j with
effect size bi that is the log-odds ratio at SNP i. ej denotes a random
sample-specific error term for sample j; ej is sampled from a stan-
dard normal distribution.
Gene expression data
Each simulated gene expression data set consisted of 1000 genes
corresponding to the 1000 genes in the SNP data set. Some of these
genes were considered risk genes that were differentially expressed
in cases and controls. We first generated baseline expression levels
for genes in the causal gene set from a multivariate normal distri-
bution X ; Nðm;SÞ. The mean vector m and the covariance matrix
+ were estimated from the P53PATHWAY based on the glioblas-
toma data. Next, we added disease effect to the causal genes in the
causal gene set based on the model xji = x0ð1 + xGji bÞ, where xji is the
expression level of gene i in sample j, x0 is the baseline expression
level of gene i in sample j, and xGji denotes the coding of the ge-
notype at SNP i for sample j in the SNP data. b is the effect size of the
genotype on gene expression and reflects the degree to which the
gene expression is correlated with the genotype of tag SNP of the
same gene. b was drawn from either U[0.5, 0.8] or U[0.5, 0.8].
The sign of b indicates up- or down-regulation of the gene. In our
simulation, gene expression variations of a causal gene in the ex-
pression data were determined by the genotypes of the same gene in
the SNP data. However, it is not realistic that all causal genes contain
both gene expression variation and genotypic variation associated
with the phenotype. To address this issue, we also simulated sce-
narios in which some causal genes contain only gene expression
variation and others include just genotypic variation. In the former
case, we first simulated a causal SNP in the SNP data set and then
simulated a causal gene in the expression data set based on this
causal SNP. Finally, we replaced this SNP with a null SNP. In the latter
case, we only added disease effect to part of the causal genes in the
expression data set. Gene expression values for null genes were also
drawn from a multivariate normal distribution, X0 ; Nðm0;S0Þ. We
estimated the average values of means and variances of all genes in
glioblastoma data and use these average values to set m0 and +0.
Glioblastoma and Crohn’s disease data
Data generated through The Cancer Genome Atlas (TCGA, http://
cancergenome.nih.gov) project for glioblastoma samples were
obtained through their data portal. The expression data set in-
cludes 258 tumor samples and 10 normal samples. The SNP data set
includes 205 tumor samples and 89 normal samples. For Crohn’s
disease (CD), expression data were generated by Wu et al. (2007)
and are available in the NCBI Gene Expression Omnibus (GEO,
http://www.ncbi.nlm.nih.gov/geo, GSE6731). The expression data
set we used contains 23 samples with seven cases versus 16 con-
trols. Cases were obtained from biopsies from affected regions of
colons of CD patients. Controls were derived from biopsies from
unaffected regions of colons of CD patients and from the colons of
healthy adults. The SNP data set includes 1748 cases and 2938
controls obtained from a published large-scale GWA study (Well-
come Trust Case Control Consortium 2007), available from the
Wellcome Trust Case Control Consortium (WTCCC, https://www.
wtccc.org.uk/info/access_to_data_samples.shtml).
We imputed missing SNP data using fastPHASE 1.4.0 (Scheet
and Stephens 2006) (http://depts.washington.edu/uwc4c/express-
licenses/assets/fastphase). We assigned SNPs that were within the
region 1 kb upstream of the TSS to the end of the transcribed bases to
be associated with a gene. Although 1 kb upstream of the TSS may be
insufficient to cover the entire regulatory region for all genes, it
should include both the core and proximal promoter regions and
at least some of the distal regulatory elements (Bortoluzzi et al.
2005). The canonical pathways from the Molecular Signatures Data-
base (MSigDB, http://www.broadinstitute.org/gsea/msigdb/index.jsp)
were used in this analysis. Pathways with less than 15 genes or more
than 100 genes in the expression data set were filtered to avoid overly
narrow or broad functional categories. This resulted in 357 canon-
ical pathways for glioblastoma data and 352 canonical pathways for
the Crohn’s disease data. Data for genes not contained in any of the
gene sets were filtered prior to performing GSAA analysis since these
data would not affect the gene set association analysis. We assessed
the statistical significance of association scores of gene sets and
adjusted for multiple hypothesis testing using 10,000 permutations
of phenotypic class labels.
Data access
GSAA software is freely available at http://gsaa.unc.edu.
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